CMS Reverses Avastin Reimbursement Limits For Macular Degeneration In Physicians' Office
This article was originally published in The Pink Sheet Daily
Executive Summary
Change comes amid criticism that new reimbursement rate would discourage use of the cheaper off-label alternative to FDA-approved Lucentis.
You may also be interested in...
OIG Raises Reimbursement Policy Questions For Avastin And Lucentis In Wake Of CATT Findings
Analysis of money spent on the treatments for wet age-related macular degeneration offers an argument for least costly alternative policy as a way of cutting health care spending.
OIG Raises Reimbursement Policy Questions For Avastin And Lucentis In Wake Of CATT Findings
Analysis of money spent on the treatments for wet age-related macular degeneration offers an argument for least costly alternative policy as a way of cutting health care spending.
Avastin v. Lucentis: An Early Test Case For Medicare ACOs?
Medicare costs for covering Genentech’s Lucentis for wet age-related macular degeneration will get heightened scrutiny now that a widely anticipated National Institutes of Health trial has confirmed that much-less-expensive treatment with the company’s Avastin is as effective.